Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity.

Brown DV, Filiz G, Daniel PM, Hollande F, Dworkin S, Amiridis S, Kountouri N, Ng W, Morokoff AP, Mantamadiotis T.

PLoS One. 2017 Feb 27;12(2):e0172791. doi: 10.1371/journal.pone.0172791. eCollection 2017.

2.

Preoperative biomarkers of tumour vascularity are elevated in patients with glioblastoma multiforme.

Bennett IE, Guo H, Kountouri N, D'abaco GM, Hovens CM, Moffat BA, Desmond P, Drummond K, Kaye AH, Morokoff AP.

J Clin Neurosci. 2015 Nov;22(11):1802-8. doi: 10.1016/j.jocn.2015.06.013. Epub 2015 Aug 22.

PMID:
26308396
3.

The peroxisome proliferator activated receptor gamma agonist pioglitazone increases functional expression of the glutamate transporter excitatory amino acid transporter 2 (EAAT2) in human glioblastoma cells.

Ching J, Amiridis S, Stylli SS, Bjorksten AR, Kountouri N, Zheng T, Paradiso L, Luwor RB, Morokoff AP, O'Brien TJ, Kaye AH.

Oncotarget. 2015 Aug 28;6(25):21301-14.

4.

Genetic interdependence of Lyn and negative regulators of B cell receptor signaling in autoimmune disease development.

Tsantikos E, Maxwell MJ, Kountouri N, Harder KW, Tarlinton DM, Hibbs ML.

J Immunol. 2012 Aug 15;189(4):1726-36. doi: 10.4049/jimmunol.1103427. Epub 2012 Jul 13.

5.

Lyn-dependent signaling regulates the innate immune response by controlling dendritic cell activation of NK cells.

Krebs DL, Chehal MK, Sio A, Huntington ND, Da ML, Ziltener P, Inglese M, Kountouri N, Priatel JJ, Jones J, Tarlinton DM, Anderson GP, Hibbs ML, Harder KW.

J Immunol. 2012 May 15;188(10):5094-105. doi: 10.4049/jimmunol.1103395. Epub 2012 Apr 9.

6.
7.

Perturbed myelo/erythropoiesis in Lyn-deficient mice is similar to that in mice lacking the inhibitory phosphatases SHP-1 and SHIP-1.

Harder KW, Quilici C, Naik E, Inglese M, Kountouri N, Turner A, Zlatic K, Tarlinton DM, Hibbs ML.

Blood. 2004 Dec 15;104(13):3901-10. Epub 2004 Aug 31.

PMID:
15339845
8.

Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos.

Stenvers KL, Tursky ML, Harder KW, Kountouri N, Amatayakul-Chantler S, Grail D, Small C, Weinberg RA, Sizeland AM, Zhu HJ.

Mol Cell Biol. 2003 Jun;23(12):4371-85.

9.

Sustained activation of Lyn tyrosine kinase in vivo leads to autoimmunity.

Hibbs ML, Harder KW, Armes J, Kountouri N, Quilici C, Casagranda F, Dunn AR, Tarlinton DM.

J Exp Med. 2002 Dec 16;196(12):1593-604.

10.

Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage.

Harder KW, Parsons LM, Armes J, Evans N, Kountouri N, Clark R, Quilici C, Grail D, Hodgson GS, Dunn AR, Hibbs ML.

Immunity. 2001 Oct;15(4):603-15.

Supplemental Content

Loading ...
Support Center